Development of bioactive peptides as antimicrobial agents: Exploring mechanisms of action
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
The antimicrobial resistance crisis has rendered entire classes of conventional antibiotics ineffective against priority pathogens, creating an urgent demand for alternative therapeutic strategies [1]. This research describes the design, synthesis, and mechanistic evaluation of six novel bioactive peptides as potential antimicrobial agents against multidrug-resistant bacterial strains. We conducted the experimental work at two Italian academic institutions between September 2021 and March 2022. Peptides were designed through computational screening of amphipathic helical sequences and synthesized via solid-phase Fmoc chemistry. Minimum inhibitory concentrations were determined against a panel of seven clinically relevant bacterial strains including MRSA, ESBL-producing Escherichia coli, and carbapenem-resistant Klebsiella pneumoniae. Peptide IT-E5 demonstrated the broadest antimicrobial spectrum with MIC values of 1 μg/mL against MRSA and 4 μg/mL against extensively drug-resistant Acinetobacter baumannii. IT-B3 showed particular potency against Gram-positive organisms with an MIC of 1 μg/mL against Streptococcus pyogenes. Time-kill kinetics revealed rapid bactericidal activity, with IT-E5 achieving 98.1% bacterial killing at 2× MIC within four hours. Mechanistic investigations using propidium iodide uptake assays and SYTOX Green staining confirmed that all six peptides act primarily through membrane disruption, causing rapid permeabilization of bacterial cell membranes. Scanning electron microscopy showed extensive surface blebbing and membrane collapse in peptide-treated bacteria. The safety profile was encouraging: IT-E5 and IT-B3 exhibited hemolysis rates below 10% at concentrations up to 32 μg/mL, indicating a therapeutic window of at least 8-fold above their effective antimicrobial concentrations. IT-F9 and IT-C7 showed less favorable hemolytic profiles, reaching 41.7% and 32.1% hemolysis respectively at 64 μg/mL, limiting their therapeutic potential without structural optimization. These findings identify IT-E5 and IT-B3 as lead candidates for further preclinical development against multidrug-resistant infections.
Fields of Study & Subjects
Antimicrobial Peptides and Activities
Antimicrobial agents and applications
Chemical Synthesis and Analysis
Publication details
- Journal / source
- International Journal of Pharmacology and Pharmaceutical Research
- Volume
- 8
- Issue
- 1
- Pages
- 11–16
- Publication date
- 1 January 2026
- Language
- EN